Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

April 5 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s (ABBV.N), opens new tab blockbuster ...

Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie 's Humira are plummeting as the once-top-selling drug fights ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...

AbbVie’s Humira sales slipped last year as the Big Pharma dealt with the first real generic erosion of its immunology megablockbuster, but its backup meds will be more than enough to not just shore up ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

AbbVie (NYSE:ABBV) has continued to maintain near 100% market share for its blockbuster arthritis therapy Humira (adalimumab) despite the U.S. market entry of vastly discounted biosimilars more than a ...